Abstract
Over the past 20 years, naturally occurring mutations that affect G protein-coupled receptors (GPCRs) have been identified, mainly in patients with endocrine diseases. The study of loss-of-function or gain-of-function mutations has contributed to our understanding of the pathophysiology of several diseases with classic hypophenotypes or hyperphenotypes of the target endocrine organs, respectively. Simultaneously, study of the mutant receptors ex vivo was instrumental in delineating the relationships between the structure and function of these important physiological and pharmacological molecules. Now that access to the crystallographic structure of a few GPCRs is available, the mechanics of these receptors can be studied at the atomic level. Progress in the fields of cell biology, molecular pharmacology and proteomics has also widened our view of GPCR functions. Initially considered simply as guanine nucleotide exchange factors capable of activating G protein-dependent regulatory cascades, GPCRs are now known to display several additional characteristics, each susceptible to alterations by disease-causing mutations. These characteristics include functionally important basal activity of the receptor; differential activation of various G proteins; differential activation of G protein-dependent and independent effects (biased agonism); interaction with proteins that modify receptor function; dimerization-dependent effects; and interaction with allosteric modulators. This Review attempts to illustrate how natural mutations of GPCR could contribute to our understanding of these novel facets of GPCR biology.
Key Points
-
G protein-coupled receptors (GPCRs) are the largest family of transmembrane receptors
-
GPCRs are key factors in endocrinology, as they are the main sensors of the internal environment
-
Hereditary and congenital forms of classic endocrine diseases that display hypophenotyes or hyperphenotypes of the target endocrine organs are attributable to loss-of-function or gain-of-function mutations of GPCRs, respectively
-
In addition to their canonical role as guanine nucleotide exchange factors, GPCRs have a series of G protein-independent effects that might be the cause of many endocrine diseases
-
Endocrine phenotypes resulting from mutations that affect noncanonical functions of GPCRs remain to be identified
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hirai, T., Subramaniam, S. & Lanyi, J. K. Structural snapshots of conformational changes in a seven-helix membrane protein: lessons from bacteriorhodopsin. Curr. Opin. Struct. Biol. 19, 433–439 (2009).
Fredriksson, R., Lagerström, M. C., Lundin, L. G. & Schiöth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256–1272 (2003).
Lania, A. G., Mantovani, G. & Spada, A. Mechanisms of disease: Mutations of G proteins and G-protein-coupled receptors in endocrine diseases. Nat. Clin. Pract. Endocrinol. Metab. 2, 681–693 (2006).
Schöneberg, T. et al. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol. Ther. 104, 173–206 (2004).
Thompson, M. D., Percy, M. E., McIntyre Burnham, W. & Cole, D. E. G protein-coupled receptors disrupted in human genetic disease. Methods Mol. Biol. 448, 109–137 (2008).
Spiegel, A. M. Inherited endocrine diseases involving G proteins and G protein-coupled receptors. Endocr. Dev. 11, 133–144 (2007).
Lefkowitz, R. J. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci 25, 413–422 (2004).
Lefkowitz, R. J. Seven transmembrane receptors: something old, something new. Acta Physiol. (Oxf) 190, 9–19 (2007).
Palczewski, K. et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739–745 (2000).
Rosenbaum, D. M., Rasmussen, S. G. & Kobilka, B. K. The structure and function of G-protein-coupled receptors. Nature 459, 356–363 (2009).
Jaakola, V. P. et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211–1217 (2008).
Tate, C. G. & Schertler, G. F. Engineering G protein-coupled receptors to facilitate their structure determination. Curr. Opin. Struct. Biol. 19, 386–395 (2009).
GPCRDB information system for G protein-coupled receptors [online],http://www.gpcr.org/7tm/ (2010).
GPCR natural variants database [online],http://nava.liacs.nl/ (2007).
TinyGRAP mutant database [online],http://www.cmbi.ru.nl/tinygrap/credits/ (2010).
Cotecchia, S., Exum, S., Caron, M. G. & Lefkowitz, R. J. Regions of the α1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc. Natl Acad. Sci. USA 87, 2896–2900 (1990).
Kjelsberg, M. A., Cotecchia, S., Ostrowski, J., Caron, M. G. & Lefkowitz, R. J. Constitutive activation of the α1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J. Biol. Chem. 267, 1430–1433 (1992).
Hofmann, K. P. et al. A G protein-coupled receptor at work: the rhodopsin model. Trends Biochem. Sci. 34, 540–552 (2009).
Scheerer, P. et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497–502 (2008).
Rasmussen, S. G. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175–180 (2011).
Samama, P., Cotecchia, S., Costa, T. & Lefkowitz, R. J. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625–4636 (1993).
Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373–386 (2010).
Bockaert, J., Perroy, J., Bécamel, C., Marin, P. & Fagni, L. GPCR interacting proteins (GIPs) in the nervous system: roles in physiology and pathologies. Annu. Rev. Pharmacol. Toxicol. 50, 89–109 (2010).
Ritter, S. L. & Hall, R. A. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 10, 819–830 (2009).
Lohse, M. J. Dimerization in GPCR mobility and signaling. Curr. Opin. Pharmacol. 10, 53–58 (2010).
Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2, 274–286 (2001).
Tarnow, P. et al. A heterozygous mutation in the third transmembrane domain causes a dominant-negative effect on signalling capability of the MC4R. Obes. Facts 1, 155–162 (2008).
Biebermann, H. et al. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 52, 2984–2988 (2003).
Mendes, H. F., van der Spuy, J., Chapple, J. P. & Cheetham, M. E. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol. Med. 11, 177–185 (2005).
Granell, S., Mohammad, S., Ramanagoudr-Bhojappa, R. & Baldini, G. Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. Mol. Endocrinol. 24, 1805–1821 (2010).
Lubrano-Berthelier, C. et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J. Clin. Endocrinol. Metab. 91, 1811–1818 (2006).
Calebiro, D. et al. Intracellular entrapment of wild-type TSH receptor by oligomerization with mutants linked to dominant TSH resistance. Hum. Mol. Genet. 14, 2991–3002 (2005).
Alberti, L. et al. Germline mutations of TSH receptor gene as cause of nonautoimmune subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 87, 2549–2555 (2002).
Themmen, A. P. N. & Huhtaniemi, I. T. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr. Rev. 21, 551–583 (2000).
Latronico, A. C. et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N. Engl. J. Med. 334, 507–512 (1996).
Martari, M. & Salvatori, R. Chapter 3 diseases associated with growth hormone-releasing hormone receptor (GHRHR) mutations. Prog. Mol. Biol. Transl. Sci. 88, 57–84 (2009).
Bédécarrats, G. Y. & Kaiser, U. B. Mutations in the human gonadotropin-releasing hormone receptor: insights into receptor biology and function. Semin. Reprod. Med. 25, 368–378 (2007).
Collu, R. et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J. Clin. Endocrinol. Metab. 82, 1561–1565 (1997).
Bonomi, M. et al. A family with complete resistance to thyrotropin-releasing hormone. N. Engl. J. Med. 360, 731–734 (2009).
de Roux, N. GnRH receptor and GPR54 inactivation in isolated gonadotropic deficiency. Best Pract. Res. Clin. Endocrinol. Metab. 20, 515–528 (2006).
Hlavackova, V. et al. Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J. 24, 499–509 (2005).
Damian, M., Martin, A., Mesnier, D., Pin, J. P. & Banères, J. L. Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J. 25, 5693–5702 (2006).
Parenty, G., Appelbe, S. & Milligan, G. CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem. J. 412, 245–256 (2008).
Han, Y., Moreira, I. S., Urizar, E., Weinstein, H. & Javitch, J. A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 5, 688–695 (2009).
Riccardi, D. & Brown, E. M. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Physiol. Renal Physiol. 298, F485–F499 (2010).
Abreu, A. P., Kaiser, U. B. & Latronico, A. C. The role of prokineticins in the pathogenesis of hypogonadotropic hypogonadism. Neuroendocrinology 91, 283–290 (2010).
Dodé, C. et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet. 2, e175 (2006).
Sarfati, J. et al. A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. J. Clin. Endocrinol. Metab. 95, 659–669 (2010).
Tao, Y. X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr. Rev. 31, 506–543 (2010).
Srinivasan, S. et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest. 114, 1158–1164 (2004).
Pantel, J. et al. Recessive isolated growth hormone deficiency and mutations in the ghrelin receptor. J. Clin. Endocrinol. Metab. 94, 4334–4341 (2009).
Pantel, J. et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest. 116, 760–768 (2006).
Liu, G., Fortin, J. P., Beinborn, M. & Kopin, A. S. Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities. J. Pharmacol. Exp. Ther. 322, 1036–1043 (2007).
Holst, B. & Schwartz, T. W. Ghrelin receptor mutations—too little height and too much hunger. J. Clin. Invest. 116, 637–641 (2006).
Claeysen, S. et al. A conserved Asn in TM7 of the TSH receptor is a common requirement for activation by both mutations and its natural agonist. FEBS Lett. 517, 195–200 (2002).
Chang, W. C. et al. Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor. PLoS ONE 2, e1317 (2007).
Grasberger, H., Van Sande, J., Hag-Dahood Mahameed, A., Tenenbaum-Rakover, Y. & Refetoff, S. A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. J. Clin. Endocrinol. Metab. 92, 2816–2820 (2007).
Parameswaran, N. & Spielman, W. S. RAMPs: the past, present and future. Trends Biochem. Sci. 31, 631–638 (2006).
Bailey, R. J., Bradley, J. W., Poyner, D. R., Rathbone, D. L. & Hay, D. L. Functional characterization of two human receptor activity-modifying protein 3 variants. Peptides 31, 579–584 (2010).
Metherell, L. A., Chan, L. F. & Clark, A. J. The genetics of ACTH resistance syndromes. Best Pract. Res. Clin. Endocrinol. Metab. 20, 547–560 (2006).
Hughes, C. R. et al. Missense mutations in the melanocortin 2 receptor accessory protein that lead to late onset familial glucocorticoid deficiency type 2. J. Clin. Endocrinol. Metab. 95, 3497–3501 (2010).
Metherell, L. A. et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat. Genet. 37, 166–170 (2005).
Bertaso, F. et al. PICK1 uncoupling from mGluR7a causes absence-like seizures. Nat. Neurosci. 11, 940–948 (2008).
Klenk, C. et al. Formation of a ternary complex between NHERF1, β-arrestin, and parathyroid hormone receptor. J. Biol. Chem. 285, 30355–30362 (2010).
Halls, M. L. & Cooper, D. M. Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, β-arrestin 2, PDE4D3 complex. EMBO J. 29, 2772–2787 (2010).
Feldman, B. J. et al. Nephrogenic syndrome of inappropriate antidiuresis. N. Engl. J. Med. 352, 1884–1890 (2005).
Decaux, G. et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J. Am. Soc. Nephrol. 18, 606–612 (2007).
Kero, J. et al. Thyrocyte-specific Gq/G11 deficiency impairs thyroid function and prevents goiter development. J. Clin. Invest. 117, 2399–2407 (2007).
Winkler, F. et al. A new phenotype of nongoitrous and nonautoimmune hyperthyroidism caused by a heterozygous thyrotropin receptor mutation in transmembrane helix 6. J. Clin. Endocrinol. Metab. 95, 3605–3610 (2010).
Parma, J. et al. Diversity and prevalence of somatic mutations in the TSH receptor and Gsα genes as a cause of toxic thyroid adenomas. J. Clin. Endocrinol. Metab. 82, 2695–2701 (1997).
Corvilain, B., Van Sande, J., Dumont, J. E. & Vassart, G. Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. (Oxf) 55, 143–158 (2001).
Chanson, P., Salenave, S. & Orcel, P. McCune-Albright syndrome in adulthood. Pediatr. Endocrinol. Rev. 4 (Suppl. 4), 453–462 (2007).
Shenker, A. Activating mutations of the lutropin choriogonadotropin receptor in precocious puberty. Receptors Channels 8, 3–18 (2002).
Liu, G. et al. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N. Engl. J. Med. 341, 1731–1736 (1999).
Kudo, M., Osuga, Y., Kobilka, B. K. & Hsueh, A. J. Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop. J. Biol. Chem. 271, 22470–22478 (1996).
Vassart, G., Pardo, L. & Costagliola, S. A molecular dissection of the glycoprotein hormone receptors 3. Trends Biochem. Sci. 29, 119–126 (2004).
Simoni, M., Gromoll, J. & Nieschlag, E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr. Rev. 18, 739–773 (1997).
Teles, M. G. et al. A GPR54-activating mutation in a patient with central precocious puberty. N. Engl. J. Med. 358, 709–715 (2008).
Fujiwara, T. M. & Bichet, D. G. Molecular biology of hereditary diabetes insipidus. J. Am. Soc. Nephrol. 16, 2836–2846 (2005).
Rochdi, M. D. et al. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol. Pharmacol. 77, 836–845 (2010).
Devedjian, J. C. et al. Transgenic mice overexpressing α2A-adrenoceptors in pancreatic β-cells show altered regulation of glucose homeostasis. Diabetologia 43, 899–906 (2000).
Rosengren, A. H. et al. Overexpression of α2A-adrenergic receptors contributes to type 2 diabetes. Science 327, 217–220 (2010).
Egbuna, O. I. & Brown, E. M. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract. Res. Clin. Rheumatol. 22, 129–148 (2008).
Vargas-Poussou, R. et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J. Am. Soc. Nephrol. 13, 2259–2266 (2002).
Rubin, C. J. et al. Whole-genome resequencing reveals loci under selection during chicken domestication. Nature 464, 587–591 (2010).
Hanon, E. A. et al. Effect of photoperiod on the thyroid-stimulating hormone neuroendocrine system in the European hamster (Cricetus cricetus). J. Neuroendocrinol. 22, 51–55 (2010).
Nakao, N. et al. Thyrotrophin in the pars tuberalis triggers photoperiodic response. Nature 452, 317–322 (2008).
Henke, A. & Gromoll, J. New insights into the evolution of chorionic gonadotrophin. Mol. Cell. Endocrinol. 291, 11–19 (2008).
Rodien, P. et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N. Engl. J. Med. 339, 1823–1826 (1998).
Smits, G. et al. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N. Engl. J. Med. 349, 760–766 (2003).
Vasseur, C. et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N. Engl. J. Med. 349, 753–759 (2003).
Montanelli, L. et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J. Clin. Endocrinol. Metab. 89, 1255–1258 (2004).
De Leener A. et al. Identification of the first germline mutation in the extracellular domain of the follitropin receptor responsible for spontaneous ovarian hyperstimulation syndrome. Hum. Mutat. 29, 91–98 (2008).
De Leener A. et al. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J. Clin. Endocrinol. Metab. 91, 555–562 (2006).
Smits, G. et al. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J. 22, 2692–2703 (2003).
Russo, D. et al. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene 11, 1907–1911 (1995).
Spambalg, D. et al. Structural studies of the thyrotropin receptor and Gsα in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J. Clin. Endocrinol. Metab. 81, 3898–3901 (1996).
d'Alva, C. B. et al. A single somatic activating Asp578His mutation of the luteinizing hormone receptor causes Leydig cell tumour in boys with gonadotropin-independent precocious puberty. Clin. Endocrinol. (Oxf) 65, 408–410 (2006).
van Boxtel R. et al. Systematic generation of in vivo G protein-coupled receptor mutants in the rat. Pharmacogenomics J. doi:10.1038/tpj.2010.44.
Calebiro, D., Nikolaev, V. O., Persani, L. & Lohse, M. J. Signaling by internalized G-protein-coupled receptors. Trends Pharmacol. Sci. 31, 221–228 (2010).
Neumann, S., Geras-Raaka, E., Marcus-Samuels, B. & Gershengorn, M. C. Persistent cAMP signaling by thyrotropin (TSH) receptors is not dependent on internalization. FASEB J. 24, 3992–3999 (2010).
Topaloglu, A. K. et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat. Genet. 41, 354–358 (2009).
Feng, S. et al. INSL3/RXFP2 signaling in testicular descent. Ann. NY Acad Sci 1160, 197–204 (2009).
Vassart, G. in Endocrinology (eds Jameson, J. L. & De Groot, L. J.) 1712–1720 (Saunders, Philadelphia, 2010).
Thakker, T. V., Bringhurst, F. R. & Jüppner, H. in Endocrinology (eds Jameson, J. L. & De Groot, L. J.) 1136–1175 (Saunders, Philadelphia, 2010).
Vilardaga, J.-P., Agnati, L. F., Fuxe, K. & Ciruela, F. G-protein-coupled receptor heteromer dynamics. J. Cell Sci. 123, 4215–4220 (2010).
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to all aspects of this Review.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Vassart, G., Costagliola, S. G protein-coupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol 7, 362–372 (2011). https://doi.org/10.1038/nrendo.2011.20
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.20
This article is cited by
-
Mechanical regulation of bone remodeling
Bone Research (2022)
-
Yeast-based directed-evolution for high-throughput structural stabilization of G protein-coupled receptors (GPCRs)
Scientific Reports (2022)
-
G protein-coupled receptors that influence lifespan of human and animal models
Biogerontology (2022)
-
The effect of Tributyltin on thyroid follicular cells of adult male albino rats and the possible protective role of green tea: a toxicological, histological and biochemical study
Egyptian Journal of Forensic Sciences (2017)
-
Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Nature Reviews Drug Discovery (2017)